Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic Warfarin therapy

Blood Coagulation and Fibrinolysis

Volumn 8, Issue 1, 1997, Pages 48-53

  Lind, S E ^a,d   Callas, P W ^a   Golden, E A ^b   Joyner Jr , K A ^c   Ortel, T L ^c  

^a UNIVERSITY OF VERMONT   (United States)

^b FLETCHER ALLEN HEALTH CARE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d EVANSTON HOSPITAL   (United States)

Author keywords

anticoagulation; factor II; factor VII; factor X; international normalized ratio; Warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; PROTHROMBIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; HUMAN; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MONITORING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOSIS;

EID: 0030994529     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199701000-00008     Document Type: Article

References (15)

1. Hirsh J, Ginsberg JS, Marder VJ. Anticoagulant therapy with coumarin agents. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemastasis and Thrombosis. Basic principles and clinical practice. 3rd edition. Philadelphia: J.B. Lippincott, 1994; 1567-1583.
2. Sise HS, Lavelle SM, Adamis D, Becker R. Relation of hemorrhage and thrombosis to prothrombin during treatment with coumarin-type anticoagulants. N Engl J Med 1958; 259: 266-271.
3. Furie B, Liebman HA, Blanchard RA, Coleman M, Kruger SF, Furie BC. Comparison of the native prothrombin antigen and the prothrombin time for monitoring oral anticoagulant therapy. Blood 1984; 64: 445-451.
4. Xi M, Béguin S, Hemker HC. The relative importance of the factors II, VII, IX and for the prothrombinase activity in plasma of orally anticoagulated patients. Thromb Hemostas 1989; 67: 788-791.
5. Andrew M, Schmidt B, Mitchell L, Paes B, Ofosu F. Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin. Thromb Haemost 1990; 63: 27-30.
6. Furie B, Diuguid CF, Jacobs M, Diuguid DL, Furie BC. Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy. Blood 1990; 75: 344-349.
7. Kornberg A, Francis CW, Pellegrini VD, Gabriel KR, Marder VJ. Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxis. Circulation 1993; 88: 454-460.
8. Zivelin A, Rao LVM, Rapaport SI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest 1993; 92: 2131-2140.
9. Loeligcr EA, van der Esch B, Mattem MJ, den Brabander ASA. Behaviour of factors II, VII, IX, and X during long-term treatment with coumarin. Thromb Diath Haemorrh 1963; 9: 74-89.
10. Paul B, Oxley A, Brigham K, Cox T, Hamilton PJ. Factor II, VII, IX and X concentrations in patients receiving long term warfarin. J Clin Pathol 1987; 40: 94-98.
11. Kumar S, Haigh JRM, Tate G, et al. Effect of warfarin on plasma concentrations of vitamin K dependent coagulation factors in patients with stable control and monitored compliance. Br J Haematol 1990; 74: 82-85.
12. Le DT, Weibert RT, Sevillar BK, Donnelly KJ, Rapaport SI. The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. Ann Intern Med 1994; 120: 552-558.
13. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108: 231S-246S.
14. Blanchard RA, Furie BC, Kruger SF, Waneck G, Jorgensen MJ, Furie B. Immunoassays of human prothrombin species which correlate with functional coagulant activities. J Lab Clin Med 1983; 101: 242-255.
15. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154: 1449-1457.